A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Tizanidine (Ontralfy)

Tizanidine is indicated for the treatment of spasticity in adults.

First FDA approval2002-07-03
Generic availableYes · 18 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$117.4M in CY2024 Part D spend10.6M claims · 3.6M beneficiaries · 329 plans surveyed

Lowest NADAC
$0.031/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.031
Across all dosage forms in distribution.
Highest NADAC
$0.033
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Tizanidine used for?

Tizanidine is indicated for the treatment of spasticity in adults.

Is there a generic for Tizanidine?

Yes. 50 ANDAs filed at FDA, 18 generic manufacturers currently shipping.

How much does my plan pay for Tizanidine?

Across 329 Part D plans, Tizanidine averages $0.031/unit (NADAC). Lowest available: $0.031/unit. Highest in distribution: $0.033/unit.

Is Tizanidine on the FDA shortage list?

No. Tizanidine is not currently on the FDA Drug Shortage Database.

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Skeletal Muscle Relaxant2 alternatives in D1
01
Cyclobenzaprine
Brand: AMRIX
$0.018Lowest NADAC
15Generic mfrs
$98.4MCY24 Part D spend
Compare →
02
Dantrolene
Brand: Dantrium
$0.410Lowest NADAC
4Generic mfrs
$5.4MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.